ClinicalTrials.gov
public full text
Public Domain
Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis
The primary objective of the study is to explore the efficacy and safety of ATryn® (antithrombin alfa) for the treatment of disseminated intravascular coagulation (DIC) associated with severe sepsis, when administered by continuous intravenous (IV) infusion over five days.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Peripheral Artery Disease and Sepsis Outcomes#804001
- Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections#1095573
- Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding#1060261
- Effect of Renin-Angiotensin System on Platelet in Patient With Sepsis#1075635
- Image 3_Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.tif#414779
Record · ID 1102113
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive